Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Corey A. Carter*, Karen Zeman, Regina M. Day, Patrick Richard, Arnold Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski, Bryan Oronsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific "driver" mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, "elephant in the room", is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to "prime" tumors and reverse resistance.

Original languageEnglish
Pages (from-to)40781-40791
Number of pages11
Issue number26
StatePublished - 2016
Externally publishedYes


  • Epigenetics
  • Non small cell lung cancer
  • Oncology
  • Resistance


Dive into the research topics of 'Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies'. Together they form a unique fingerprint.

Cite this